Lv1
10 积分 2024-09-03 加入
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
14小时前
待确认
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
14小时前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
16天前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
24天前
已完结
Sepsis
30天前
已完结
Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials
9个月前
已完结
Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials
9个月前
已完结
Toripalimab-Associated Arthritis and Peripheral Neuropathy
9个月前
已完结
Peripheral nervous system immune-related adverse events due to checkpoint inhibition
9个月前
已完结
Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy
9个月前
已完结
皖公网安备34019202002308
